NASDAQ:FOLD
Amicus Therapeutics Stock News
$9.48
-0.660 (-6.51%)
At Close: May 09, 2024
Amicus Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
07:00am, Monday, 26'th Apr 2021
PHILADELPHIA, April 26, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 10, 2021 at 8:30
Why Amicus Therapeutics Stock Is Soaring Today
12:33pm, Wednesday, 14'th Apr 2021
Investors cheered an analyst's upgrade of the biotech stock.
Amicus Therapeutics' (FOLD) CEO John Crowley on Q4 2020 Results - Earnings Call Transcript
01:02pm, Monday, 01'st Mar 2021
Amicus Therapeutics' (FOLD) CEO John Crowley on Q4 2020 Results - Earnings Call Transcript
Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates
09:07am, Monday, 01'st Mar 2021
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -12.50% and 0.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview for Amicus Therapeutics
10:10am, Friday, 26'th Feb 2021
Amicus Therapeutics (NASDAQ:FOLD) unveils its next round of earnings this Monday, March 01. Get prepared with Benzinga's ultimate preview for Amicus Therapeutics's Q4 earnings.
Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know
01:39pm, Monday, 22'nd Feb 2021
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Stock Plunges After Rare-Disease Drug Misses In Key Study
11:16am, Friday, 12'th Feb 2021
Amicus Therapeutics said Thursday its rare-disease treatment failed to outperform a standard drug on one key measure in a Phase 3 test. In response, FOLD stock plunged on Friday.
SVB Leerink, J.P. Morgan downgrade Amicus stock after Phase 3 data for rare disease drug comes out
07:55am, Friday, 12'th Feb 2021
Shares of Amicus Therapeutics Inc. were down 23.1% in premarket trading on Friday, the day after the company said an experimental rare disease drug failed to perform better than the standard of care i
John Crowley, Amicus Therapeutics, discusses drug trial results for Pompe disease
06:32pm, Thursday, 11'th Feb 2021
CNBC Meg Tirrell talks with Amicus Therapeutics CEO John Crowley about trial results for a drug to treat Pompe disease. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Kare
Amicus releases phase 3 results in Pompe disease trial
05:06pm, Thursday, 11'th Feb 2021
CNBC's senior health and science reporter Meg Tirrell reports Amicus showed results in its phase 3 trial to address Pompe disease. The drug showed it can help people walk and significantly slowed the
Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021
Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021
02:30pm, Monday, 08'th Feb 2021
Amicus Optimized Transgene Show Greater Substrate Reduction than Wild Type Construct Across All Tissues and Doses
Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options
09:47am, Thursday, 28'th Jan 2021
Investors need to pay close attention to Amicus Therapeutics (FOLD) stock based on the movements in the options market lately.
Amicus Therapeutics Announces Presentations and Posters at the 17th Annual WORLDSymposium™ 2021
07:00am, Thursday, 21'st Jan 2021
CRANBURY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines
Amicus Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
07:00am, Tuesday, 05'th Jan 2021
CRANBURY, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the 39th Annual J.P. Mo